STAT Plus: New York panel seeks extra Medicaid rebates from Biogen for pricey rare disease drug

A New York State panel has recommended that officials seek a supplemental Medicaid rebate for a pricey rare disease drug sold by Biogen (BIIB), marking only the third time such a move was proposed because a medicine may cause the state Medicaid program to exceed a cap on drug spending.

In a 14-to-0 vote last Thursday, the state’s Drug Utilization Review panel agreed that a rebate should be pursued for Spinraza, which is used to treat muscular spinal atrophy, an often-fatal genetic disease affecting muscle strength and movement. In its deadliest form, referred to as Type 1, the disease causes children to die by the time they turn 2 years old.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: New York panel seeks extra Medicaid rebates from Biogen for pricey rare disease drug »